Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
INTERPACE BIOSCIENCES, INC. (IDXG)
|
Add to portfolio |
|
|
|
| Price: |
$7.95
| | Metrics |
| OS: |
4.31
|
M
| |
|
|
| Market cap: |
$34.3
|
M
| |
|
|
|
Net debt:
|
$7.73
|
M
| |
2.0
|
x Debt/EBITDA
|
|
EV:
|
$42
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$3.8
|
M
| |
11.0
|
x EV/EBITDA
|
|
EBIT
|
$2.1
|
M
| |
20.0
|
x EV/EBIT
|
| EPS |
$2.72
| |
2.9
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 31.8 | 33.1 | 32.4 | 24.2 | 21.9 | 15.9 | 13.1 | 9.4 |
| Revenue growth | -3.9% | 2.2% | 33.8% | 10.6% | 37.7% | 21.5% | 38.7% | 539.9% |
| Cost of goods sold | 13.6 | 14.3 | 21.7 | 15.9 | 10.2 | 7.4 | 6.6 | 6.9 |
| Gross profit | 18.2 | 18.8 | 10.7 | 8.3 | 11.7 | 8.5 | 6.4 | 2.5 |
| Gross margin | 57.3% | 56.8% | 33.1% | 34.4% | 53.4% | 53.7% | 49.2% | 26.7% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 9.1 | 9.2 | 9.3 | 11.1 | 8.4 | 6.6 | 5.5 | 10.4 |
| Research and development | 0.7 | 1.5 | 2.8 | 2.8 | 2.1 | 1.5 | 1.6 | 2.3 |
| General and administrative | 11.0 | 10.7 | 20.8 | 14.4 | 8.7 | 9.2 | 10.5 | 16.9 |
| EBITA | -1.6 | -2.6 | -21.1 | -19.9 | -7.5 | -8.6 | -11.2 | -28.3 |
| EBITA margin | -5.1% | -7.8% | -65.1% | -82.4% | -34.3% | -54.4% | -85.4% | -299.9% |
| Amortization of intangibles | 1.3 | 3.2 | 6.0 | 4.0 | 3.6 | 3.3 | 3.8 | 3.8 |
| EBIT | -2.9 | -5.8 | -27.1 | -23.9 | -11.1 | -11.9 | -14.9 | -32.1 |
| EBIT margin | -9.1% | -17.4% | -83.7% | -98.9% | -50.7% | -74.8% | -114.2% | -340.3% |
| Pre-tax income | -5.8 | -7.7 | -26.1 | -26.7 | -12.7 | -13.1 | -8.6 | -44.2 |
| Income taxes | 0.0 | -0.7 | 0.1 | 0.0 | 0.0 | -0.4 | -0.2 | -13.1 |
| Tax rate | | 9.1% | | 0.1% | | 3.0% | 1.9% | 29.7% |
| Earnings from continuing ops | 10.2 | 0.9 | -29.2 | -27.1 | -12.7 | -12.7 | -8.4 | -31.1 |
| Earnings from discontinued ops | -16.1 | -7.9 | -0.3 | -0.1 | 0.0 | 0.5 | | |
| Net income | -5.9 | -7.0 | -29.5 | -27.2 | -12.7 | -12.2 | -8.3 | -11.4 |
| Net margin | -18.4% | -21.2% | -91.0% | -112.2% | -58.0% | -76.8% | -63.7% | -120.4% |
| |
| Diluted EPS | $2.41 | $0.21 | ($7.26) | ($7.23) | ($4.52) | ($0.81) | ($4.63) | ($20.07) |
| Shares outstanding (diluted) | 4.2 | 4.1 | 4.0 | 3.7 | 2.8 | 15.8 | 1.8 | 1.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|